Large-cap Health Care company DexCom has logged a -1.0% change today on a trading volume of 405,084. The average volume for the stock is 4,175,171.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. Based in San Diego, United States the company has 9,500 full time employees and a market cap of $29,833,646,080.
The company is now trading -20.52% away from its average analyst target price of $96.1 per share. The 24 analysts following the stock have set target prices ranging from $75.0 to $120.0, and on average give DexCom a rating of buy.
Over the last 12 months DXCM shares have declined by -37.4%, which represents a difference of -65.1% when compared to the S&P 500. The stock's 52 week high is $142.0 per share and its 52 week low is $62.34. Based on DexCom's average net margin growth of 14.4% over the last 6 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 3,622,300 | 541,500 | 15 | 25.0 |
| 2022 | 2,909,800 | 341,200 | 12 | 33.33 |
| 2021 | 2,448,500 | 216,900 | 9 | -67.86 |
| 2020 | 1,926,700 | 549,700 | 28 | 300.0 |
| 2019 | 1,476,000 | 101,100 | 7 | 158.33 |
| 2018 | 1,031,600 | -127,100 | -12 |
